Table 1 Clinical and pathological data for SCEO and ECOM patients
From: Comparison and analysis of the clinicopathological features of SCEO and ECOM
SCEO (N = 51) | ECOM (N = 60) | P | |
|---|---|---|---|
MEAN AGE (Y) | 53.96 | 55.41 | 0.221 |
BMI (KG/M2) | 29.31 | 28.93 | 0.245 |
MENOPAUSAL STATUS (PRE, POST) | Pre: n = 26 (51) | Pre: n = 21 (35) | 0.447 |
Post: n = 25 (49) | Post: n = 39 (65) | ||
SERUM CA-125 LEVEL (U/ML) | < 35: n = 28 (55) | < 35: n = 29 (48) | 0.87 |
> 35: n = 23 (45) | > 35: n = 31 (52) | ||
Irregular vaginal bleeding n = 24 (47) | Irregular vaginal bleeding n = 37 (62) | 0.827 | |
MAIN COMPLAINTS | Lower abdominal mass n = 19 (37) | Lower abdominal mass n = 14 (23) | |
Abdominal distention n = 8 (16) | Abdominal distention n = 9 (15) | ||
FIGO STAGE, ENDOMETRIAL CANCER | I: n = 45 (88) | I: n = 0 (0) | 0.001 |
II: n = 5 (10) | II: n = 0 (0) | ||
III: n = 1 (2) | III: n = 42 (70) | ||
IV: n = 0 (0) | IV: n = 18 (30) | ||
FIGO STAGE, OVARIAN CANCER | I: n = 32 (63) | NA | &&& |
II: n = 5 (10) | NA | ||
III: n = 14 (27) | NA | ||
IV: n = 0 (0) | NA | ||
SURGERY TYPE | TH + BSO: n = 2 (4) | TH + BSO: n = 3 (5) | 0.000 |
TH + BSO + PLA: n = 9 (18) | TH + BSO + PLA: n = 8 (13) | ||
TH + BSO + PLA + OM: n = 10 (20) | TH + BSO + PLA + OM: n = 17 (28) | ||
TH + BSO + OM: n = 4 (8) | TH + BSO + OM: n = 6 (10) | ||
TH + BSO + PLA + OM + PALA: n = 10 (20) | TH + BSO + PLA + OM + PALA: n = 15 (25) | ||
TH + BSO + PLA + OM + PALA+ 6: n = 4 (8) | TH + BSO + PLA + OM + PALA+ 6: n = 6 (10) | ||
TH + BSO + PLA + OM + 6: n = 8 (16) | TH + BSO + PLA + OM + 6: n = 3 (5) | ||
TH + BSO + 6: n = 1 (2) | TH + BSO + 6: n = 0 (0) | ||
TH + BSO + PLA + PALA: n = 3 (6) | TPH + BSO + PLA + ALA: n = 2 (3) | ||
HISTOLOGY TYPE | Endometrioid: n = 33 (65) | Endometrioid: n = 37 (62) | 0.001 |
Not Endometrioid: n = 18 (35) | Not Endometrioid: n = 23 (38) | ||
ENDOMETRIAL TUMOUR GRADE | I: n = 33 (65) | I: n = 15 (25) | 0.001 |
II-III: n = 18 (35) | II-III: n = 45 (75) | ||
MYOMETRIUM INFILTRATION DEPTH | < 1/2: n = 40 (78) | < 1/2: n = 22 (37) | 0.001 |
≥1/2: n = 11 (22) | ≥1/2: n = 38 (63) | ||
LVSI | (−): n = 38 (75) | (−): n = 19 (32) | 0.039 |
(+): n = 13 (25) | (+): n = 41 (68) | ||
LYMPH NODE METASTASIS | (−): n = 40 (78) | (−): n = 32 (53) | 0.001 |
(+): n = 4 (8) | (+): n = 20 (33) | ||
OMENTUM METASTASIS | (−): n = 30 (59) | (−): n = 24 (40) | 0.000 |
(+): n = 6 (12) | (+): n = 33 (55) | ||
POSTOPERATIVE THERAPY | Follow-up: n = 0 | Follow-up: n = 0 | 0.003 |
Chemotherapy: n = 18 (35) | Chemotherapy: n = 29 (48) | ||
Radiotherapy: n = 5 (10) | Radiotherapy: n = 2 (4) | ||
Chemoradiotherapy: n = 28 (55) | Chemoradiotherapy: n = 29 (48) |